Blue Jet Healthcare FY26 Results: Mixed Performance Driven by Segmental Shifts

Blue Jet Healthcare reported total revenue of ₹947 crore for the fiscal year 2026. The company's performance in FY26 was characterized by strong growth in its Contrast Media segment, partially offset by significant headwinds in the PI/API segment due to customer inventory destocking.

Reader Takeaway: Strong Contrast Media growth, but PI/API segment recovery and margin pressure are key watch points.

What just happened

Blue Jet Healthcare Limited reported a total revenue of ₹947 crore for FY26. The Contrast Media segment grew by 23% to ₹495 crore. Conversely, the PI/API segment revenue declined to ₹298 crore for FY26, with Q4 FY26 revenue dropping sharply to ₹2.4 crore. The Artificial Sweetener segment revenue was ₹131 crore, a 2% decline. The EBITDA margin for FY26 was 31%, down from 37% in FY25.

Why this matters

The results indicate a mixed performance, with the crucial PI/API segment facing a significant downturn attributed to customer destocking, which management states is now complete. The strong growth in Contrast Media provides a positive offset. The company's debt-free status and ₹400 crore in liquid assets position it well for its ₹1,000 crore Vizag expansion.

The backstory

FY26 represented a transitional year for Blue Jet Healthcare. The company has been investing in expansion, with a significant ₹1,000 crore Vizag project underway. Historically, the company has aimed for debt-free operations and robust liquidity.

What changes now

Management expects the PI/API segment to recover in FY27, with orders in hand following the completion of destocking. FY27 growth is anticipated to be driven by new commercial launches. Investors will be watching for the normalization of the PI/API segment and the success of new product commercialization.

Risks to watch

Key concerns include the pace of recovery in the PI/API segment and potential impacts from a regulatory warning letter received by a customer for a sole formulation plant. EBITDA margins have also seen pressure, declining from 37% in FY25 to 31% in FY26.

Peer comparison

(No direct peer comparison data provided in the filing.)

Context metrics (time-bound)

• Revenue FY26: ₹947 crore
• Contrast Media Revenue FY26: ₹495 crore
• PI/API Revenue FY26: ₹298 crore
• Artificial Sweetener Revenue FY26: ₹131 crore
• EBITDA Margin FY26: 31%
• Liquid Assets FY26: ₹400 crore
• Operating Cash Flow FY26: ₹334 crore

What to track next

Investors should monitor the Q1 FY27 and subsequent quarterly results for signs of recovery in the PI/API segment, the performance of new product launches, and the trajectory of EBITDA margins. The progress of the Vizag expansion project will also be a key focus.